More importantly, in GC patients, TREM2+ TAMs exclude CD8+ T cell infiltration and promote immune checkpoint expression on tumor-infiltrated CD8+ T cells, like PD-1, CTLA4, and TIM3, which shapes an inhibitory immune microenvironment. The gene discussed is CTLA4; the disease is neoplasm.